ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HIK Hikma Pharmaceuticals Plc

1,918.50
38.00 (2.02%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  38.00 2.02% 1,918.50 1,925.00 1,927.00 1,937.50 1,887.50 1,903.00 504,022 16:35:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.88B 190M 0.8594 22.41 4.26B
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,880.50p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,614.50p to 2,222.00p.

Hikma Pharmaceuticals currently has 221,081,676 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £4.26 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 22.41.

Hikma Pharmaceuticals Share Discussion Threads

Showing 601 to 625 of 1875 messages
Chat Pages: Latest  27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
18/5/2017
10:48
I'll buy at the late 14 early 15 handleGood LuckP
phatprofit
17/5/2017
20:45
Would be a fantastic buy if they drop to that level.
fez77
17/5/2017
18:20
seems that one of the brokers set a price of 14.50p that a big drop from £26 this year. At that price i buy so lets see what happens as sure they make profits this year plus low debts etc
mrthomas
16/5/2017
21:00
Hope so. Fingers crossed!
fez77
16/5/2017
16:10
Well I was wrong there. Perhaps we've hit the bottom.
Suet

suetballs
16/5/2017
07:35
16 here we come - looks inevitable - but fall overdone imo.
Suet

suetballs
15/5/2017
13:50
think this will be as mark cap below £5b so be down that means even more pressure onshore price looks like could hit 16 even before goes down that the case unless some good news flow could hit 15 when goes down

But still feel this is good long term but see if it hits 16 first

mrthomas
15/5/2017
13:44
This is oversold once again...

I'll continue to stay clear until it bottoms, also look out to see if directors buy any more.

Any one know what the share price would have to hit for this to get relegated into FTSE250?

qruz
15/5/2017
10:44
think at 16 would buy as brought at 17.60 and 17.80 in the past but this time want a bit more lee room as done this in the past with mining stocks and when down even more.

But at 16 given profits and low debt should be ok one hopes

mrthomas
12/5/2017
14:21
Entering Oversold territory. Based on results alone it doesn't warrant such a drop
sandeep67
12/5/2017
07:14
May play down to 1600
tsmith2
11/5/2017
08:27
Trying to work out what this will mean short term on profits Bs etc have brought in the past. It's likely this could drop from top 100 at the next review this company is not for the faint hearted that for sure
mrthomas
11/5/2017
08:11
- After receiving an unfavourable verdict from US drug regulators, Hikma Pharamceuticals and partner Vectura felt there was a "low likelihood" that their generic version of asthma treatment Advair would be approved this year.
Hikma, the proposed manufacturer of the drug, and Vectura, the maker of the inhaler, received a Complete Response Letter from the US Food and Drug Administration categorised as 'major', which means the drug application will require significant amendments.

'Major' categorisations can have two outcomes - either requiring major amendments from a large number of minor observations, or a major amendment due to a major observation such as bioequivalence or a device issue requiring further study.

Hikma said it would need to fully review the CRL and discuss it with the FDA, but both believed there was "a low likelihood of approval this year" and for Vectura this meant it does not anticipate receiving an approval milestone or sales royalties for the VR315 programme in 2017.

"Based on the initial assessment no material issues were raised regarding the substitutability of the proposed device," Hikma said.

"Hikma and Vectura are committed to bringing this important product to the US market and have confidence in the future approval of the programme as an AB rated substitutable product."

Vectura is due to receive a $11m milestone payment on approval of the abbreviated new drug application (ANDA) plus a mid-teen percentage royalty on net sales of VR315 in the US.

Investors in the drug device maker have had high hopes for this programme, with analysts at RBC recently calling VR315's approval in the US "arguably the most important launch from Vectura's pipeline for the next circa-4 years".

Numis earlier in the week pointed out that a 'major' CRL could have two outcomes.

The first would require "amendment from a larger number of what are still minor observations (possible given complexity of combination inhalers) that FDA then responds to in 10 months - this would significantly de-risk eventual approval (equivalent to previous FDA "approvable" letter) but imply a longer time to market".

The second 'major' CRL outcome could require "a major amendment due to a major observation (e.g. bioequivalence, device issue requiring further study, equivalent to previous "not approvable" letter) - this is the scenario that implies a valuation downgrade, though at current levels we see it potentially creating an attractive buying opportunity below the value of Vectura's
already approved products".

Hikma's fluticasone propionate and salmeterol inhalation powder is designed as a treatment for asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease, as part of the ANDA is delivered using Vectura's proprietary dry powder inhaler and formulation technology.

broadwood
11/5/2017
08:00
Definite market overreaction imo.
bantam175
11/5/2017
07:43
Entirely predictable. Make no mistake, this rejection of Mylan's and Hikma's products will cost the US taxpayer hundreds of millions and many lives. It is well known the FDA guys are entirely in the pockets of 'big pharma' so will reject generics like advair from small companies which have been shown to be perfectly safe, on any whim or technicality. The loser of course is the US patient forced to pay extortionate prices for their healthcare, to keep the FDA in clover and 'busy' pretending to be an independent arbiter of pharma regulation.
Given how the US healthcare system works many partially and uninsured (there are tens of millions) poorly controlled asthmatic or copd patients will die because they cannot afford expensive branded inhalers while they await the FDA prevaricators who continue to deny them affordable drugs lest it hurt the profits and bonuses of their buddies on Wall Street. If Trump wants healthcare for all and cheap drugs then a purge of the FDA gravy train sham needs to be first in his line of sight. imo

cumnor
11/5/2017
07:30
London, 11 May 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today announces that it has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) in relation to its abbreviated new drug application (ANDA) for its generic version of GlaxoSmithKline's Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder).

The FDA has categorised the CRL as 'Major'. Hikma is in the process of reviewing the response and will provide an update on its application as soon as practicable once it has completed its review of the CRL and discussed this with the FDA. Based on the initial assessment, no material issues were raised regarding the substitutability of the proposed device.

Given the nature of the feedback, Hikma believes there is a low likelihood of approval this year. Hikma is committed to bringing this important product to the US market and will work collaboratively with the FDA to address their outstanding questions.

Hikma's fluticasone propionate and salmeterol inhalation powder is indicated for the treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease and is delivered using Vectura's proprietary dry powder inhaler and formulation technology.

jurgenklopp
10/5/2017
19:19
What drug trial. Though it was news of generic approvals.
r ball
10/5/2017
12:25
thinking of buying if falls below 18.50 like last time but with news about drug trail it a risk of 50/50 see if directors buy again may be
mrthomas
02/5/2017
15:27
Pharmas on fire today.
broadwood
26/4/2017
15:42
Still moving ahead nicely.
fez77
25/4/2017
19:29
Good rise today. Hope it keeps the momentum!
fez77
25/4/2017
12:29
Yes I was daring to think the same, although the purchase was not a huge one. Here's hoping the tide has turned!
fez77
25/4/2017
07:37
Nina Handerson (director ) bought 3500 shares at £18.66. I believe we may have bottomed out.
karateboy
21/4/2017
16:03
Market is waiting for FDA approval of the generic Advair medicine.Shorters are having a go until mid May. I am surprised share price has dropped so much on a short time. As soon as these shorts are closed share price should recover again.
karateboy
21/4/2017
12:38
Interestingly the share price is now down to the same level that Darhold Ltd (the directors holding company) last bought in on 16 December for over £2M. Any repeat of that may trigger the turning point.
fez77
Chat Pages: Latest  27  26  25  24  23  22  21  20  19  18  17  16  Older

Your Recent History

Delayed Upgrade Clock